Stockscreener 앱 받기
30.86
6.63%
1.92
시간 외 거래:
30.80
-0.06
-0.19%
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Italy’s Angelini said to explore Catalyst Pharma acquisition - MSN
Hussman Strategic Advisors Inc. Sells 42,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Executive Compensation, Stock Awards, and Option Grants 2025 Overview - Minichart
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma - MSN
(CPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Executive pay, ownership and governance detailed in Catalyst (NASDAQ: CPRX) 2025 10-K/A - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Has $3.91 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived - Pharmaceutical Executive
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - TradingView
Catalyst posts Q1 results after the bell May 11; call set for 8:30 ET - Stock Titan
Angelini Pharma Considers Acquisition of Catalyst Pharmaceuticals (CPRX) - GuruFocus
BofA reiterates Catalyst Pharmaceuticals stock rating on M&A report By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals Jumps 6.8% Amid Sector-Wide Rally - AlphaStreet
Catalyst Pharmaceuticals (CPRX) Shares Surge on Acquisition Inte - GuruFocus
Catalyst Pharmaceuticals jumps on report of potential acquisition interest - Quiver Quantitative
Italy’s Angelini Said to Explore Catalyst Pharma Acquisition - Bloomberg.com
Italy's Angelini said to explore acquisition of Catalyst PharmaBloomberg News - marketscreener.com
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma (CPRX:NASDAQ) - Seeking Alpha
Catalyst Pharmaceuticals stock surges on takeover report By Investing.com - Investing.com Canada
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Italy’s Angelini Said to Explore Acquisition of Catalyst Pharma - Bloomberg.com
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution - Sahm
Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors? - Sahm
How Rare-Disease Drug Momentum At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - TradingView
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high at $26.63 - Investing.com
Is Catalyst (CPRX) stock attracting cautious sentiment | Q4 2025: Better Than ExpectedReal Time Stock Idea Network - Xã Thanh Hà
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
The Bull Case For Catalyst Pharmaceuticals (CPRX) Could Change Following Firdapse Exclusivity Win And Agamree Launch - Sahm
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Strong Buy" from Brokerages - MarketBeat
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
Price-Driven Insight from (CPRX) for Rule-Based Strategy - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Is Up 5.3% After Stronger Revenue And Expanded M&A PipelineWhat's Changed - Sahm
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Institutional Support And Deal Pipeline Shape Outlook For Catalyst Pharmaceuticals - Yahoo Finance
0.14%
0.48%
자본화:
|
볼륨(24시간):